Stryker (SYK) has been upgraded to a 'Strong Buy' following a significant price pullback to $275, presenting attractive value compared to its historical valuation. The company shows robust organic sales growth across various regions and segments, driven by strong demand and high equipment backlogs. Key growth areas include Mako robotic-assisted procedures, expansion in ambulatory surgery centers, and integration of the Smart Care platform, supporting expectations of double-digit earnings per share growth. With a strong balance sheet and status as a Dividend Aristocrat, Stryker is positioned to deliver mid to high-teens annual total returns for investors.
Following the news on Stryker's upgrade to 'Strong Buy,' the stock is trading at USD 275.60 on Pluang as of Oct 05, 2026 18:14 WIB, showing a slight increase of 0.06% for the day. The market cap stands at $116.27 billion, with the stock near its 52-week low of $269.75, indicating a recent price pullback. Investors typically hold SYK for about 22 days on Pluang, and the dividend yield is currently 1.28%.
Block & Leviton is investigating Stryker Corporation for potentially violating securities laws by allegedly misrepresenting the status of a manufacturing problem affecting its peripheral vascular business. Stryker's CEO initially claimed the issue wa...
Stryker Corporation's shares dropped 8.8% after CFO Preston Wells disclosed that a manufacturing problem in its Peripheral Vascular unit, previously thought resolved, is continuing into Q4 2026. This revelation wiped out over $10 billion in market va...
